Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
University Hospital, Essen
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
53High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06388369CT.gov Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer | — | Terminated | — | — | — |
NCT04388852CT.gov DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers | — | Active Not Recruiting | — | — | — |
NCT02601014CT.gov Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7 | — | Completed | — | — | — |
NCT00170157CT.gov Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer | — | Completed | — | — | — |
NCT00064129CT.gov Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ipilimumab (this asset) | University Hospital, Essen | P2 | BB · 66 |
| Leuporelin | Mayo Clinic | P4 | BBB |
| Enzalutamide | Pfizer | P4 | BBB |
| Prednisone | Mayo Clinic | P4 | BBB |
| Degarelix | Baptist Health South Florida | P3 | BBB |
| Abiraterone | Mayo Clinic | P4 | BBB |
| Docetaxel | Alliance for Clinical Trials in Oncology | P3 | BB |
| Goserelin | Mayo Clinic | P3 | BB |
| Fludeoxyglucose | Jonsson Comprehensive Cancer Center | P2/3 | BB |
+41 more in the Prostate Carcinoma cohort
Other indications for Ipilimumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Neoplasm | — | P3 | BB · 71 |
| Melanoma | — | P4 | BB · 69 |
| Cutaneous Melanoma | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ipilimumab in Prostate Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ipilimumab-prostate-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →